SNaRIs,NaSSAs,およびNaRIs:うつ病の治療のための新しい薬剤
1New York State Psychiatric Institute, Unit 41, New York, NY 10032, USA. JMK14@columbia.edu
Lancet (London, England)
|February 7, 2001
まとめ
セロトニン・ノラドレナリン再吸収阻害剤 (SNaRIs) と選択的ノラドレナリン再吸収阻害剤 (NaRIs) を含む4つの新しい抗うつ薬は,改善された特異性とより速い作用を提供します. これらの新薬は,異なる薬理学的プロファイルを持つ抗うつ剤療法における進歩を表しています.
科学分野:
- 薬理学 薬理学とは
- 神経科学は神経科学である.
- ドラッグ開発 ドラッグ開発
背景:
- 現在の抗うつ薬の開発は,より古い薬剤クラスと比較して,特異性を高め,より早く作用を開始することを目指しています.
- 最近,異なる薬理学的プロファイルを持つ4つの新しい抗うつ剤が導入されました.
研究 の 目的:
- 4つの新しい抗うつ薬:ヴェンラファキシン,ネファゾドン,ミルタザピン,およびレボキセチンの薬理学的特性を紹介し,説明する.
- 各新しい抗うつ剤の独特の作用機構を強調する.
主な方法:
- 4つの新しい抗うつ薬の薬理学的プロフィールのレビュー.
- 主要な作用メカニズム (例えば,再吸収抑制,受容体対抗) に基づいて抗うつ剤の分類.
主要な成果:
- ヴェンラファキシン:セロトニンノラドレナージック再吸収阻害剤 (SNaRI).
- ネファゾドン:セロトニンとノレプレインフリンの再吸収阻害剤で,強力なセロトニン5HT2受容体アンタゴニズムがある.
- ミルタザピンは,アルファ2-アドレナリンおよびセロトニン受容体に作用するノルアドレナリンおよび特定のセロトニン抗うつ剤 (NaSSA) です.
- レボキセチン: 選択的なノラドレナリン再吸収阻害剤 (NaRI) で,直接的なセロトニン効果がない.
結論:
- ヴェンラファキシン,ネファゾドン,ミルタサピン,レボキセチンの導入は,抗うつ薬の薬剤療法における進歩を意味する.
- これらの薬剤は,様々な作用メカニズムを提供し,潜在的に有効性の向上と副作用の減少につながる可能性があります.
さらに関連する動画
05:19Closed-Loop Neurostimulation for Biomarker-Driven, Personalized Treatment of Major Depressive Disorder
Published on: July 7, 2023
08:15Network Pharmacology and Validation of the Antidepressant Mechanisms of Qiangzhifang in a Chronic Restraint Stress-induced Depression Rat Model
Published on: June 6, 2025
関連する概念動画
01:21G-protein Coupled Receptors
G-protein coupled receptors are ligand binding receptors that indirectly affect changes in the cell. The actual receptor is a single polypeptide that transverses the cell membrane seven times creating intracellular and extracellular loops. The extracellular loops create a ligand specific pocket which binds to neurotransmitters or hormones. The intracellular loops holds onto the G-protein.
01:18Depression: Overview
Depression is a prevalent mental illness marked by persistent sadness and lack of interest in previously enjoyable activities. It can take several forms, including major depression, persistent depressive disorder, and bipolar I and II disorders. Symptoms range from emotional changes like chronic worry to physical changes like sleep disturbances and suicidal thoughts. From a neurobiological perspective, depression is believed to be triggered by abnormalities in the brain's prefrontal cortex,...
01:25Antidepressant Drugs: Overview
Antidepressant drugs are a class of medications primarily used for treating various mood disorders, including major depression, anxiety disorders, and other related conditions. These medicines work by modulating the neurotransmitter balance within the brain, alleviating depressive symptoms. Antidepressants can be broadly categorized into several groups according to their mechanism of action and chemical structure: Selective Serotonin Reuptake Inhibitors (SSRIs), Serotonin-Norepinephrine...
01:28Antidepressant Drugs: Tricyclics, SSRIs, and SNRIs
Tricyclic Antidepressants (TCAs), including Desipramine (Norpramin), Imipramine (Tofranil), Clomipramine (Anafranil), and Amitriptyline (Elavil), inhibit serotonin and norepinephrine reuptake and also block other receptors. They are used for depression, pain conditions, and insomnia. Common adverse effects include anticholinergic effects, sedation, orthostatic hypotension, and weight gain. They have a narrow therapeutic window and so require plasma-level monitoring. Abrupt discontinuation can...
01:23Antidepressant Drugs: MAOIs and Other Agents
Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...
01:17Sedatives and Hypnotics Drugs: Miscellaneous Agents
Sedatives and hypnotics encompass a wide range of substances, each with its unique mechanism of action, uses, and potential adverse effects.
Melatonin congeners like ramelteon (Rozerem) and tasimelteon (Hetlioz) selectively bind to melatonin receptors (MT1 and MT2) and thus mimic the actions of melatonin, a hormone that regulates sleep-wake cycles. Tasimelteon is primarily used for non-24-hour sleep-wake disorder, common in blind patients. They are also used to treat conditions like insomnia...
Melatonin congeners like ramelteon (Rozerem) and tasimelteon (Hetlioz) selectively bind to melatonin receptors (MT1 and MT2) and thus mimic the actions of melatonin, a hormone that regulates sleep-wake cycles. Tasimelteon is primarily used for non-24-hour sleep-wake disorder, common in blind patients. They are also used to treat conditions like insomnia...